SEC Form 4 · accession 0001209191-17-024853
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Marc Wilson
Officer — Chief Accounting Officer
Period of report
Mar 16, 2016
Accepted (ET)
Apr 4, 2017 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $9.89 | Mar 16, 2016 | A | 12,000 | A | — | Mar 15, 2026 | Common Stock | 12,000 | 12,000 | D |
| Employee Stock Option (right to buy)F2 | $7.80 | Mar 31, 2017 | A | 25,000 | A | — | Mar 30, 2027 | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 16, 2016.
- F2The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017.